Adolescent and young adult (AYA) cancers: Distinct biology, different therapy?

Cancer Forum

Volumn 33, Issue 1, 2009, Pages 4-10

  Bleyer, Archie ^a,b,c,d  

^a ST CHARLES MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ARSENIC TRIOXIDE; ETOPOSIDE; IFOSFAMIDE; RETINOIC ACID; TAMOXIFEN; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; BREAST CANCER; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; KARYOTYPE; NEOPLASM; PROGNOSIS; REVIEW; SARCOMA;

EID: 63649096246     PISSN: 0311306X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Department of Health and Human Services, National Institutes of Health, National Cancer Institute and the LiveStrong Young Adult Alliance. Closing the gap: Research and care imperatives for adolescents and young adults with cancer. A report of the Adolescent and Young Adult Oncology Program Review Group. 2006. Available from: http://planning.cancer.gov/ disease/AYAO_PRG_Report_2006_FINAL.pdf.
2. National Cancer Institute. Meeting notes on young adults with cancer. NCI Cancer Bulletin. 2006 Nov 21;3(45):1. Available from: www.cancer.gov/ ncicancerbulletin/NCI_Cancer_Bulletin_112106/page7?cb_email=1.
3. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008 8(4):288-98.
4. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Hemat. Jan 2009 144(2):147-56.
5. Rowley JD. Chromosomal translocations: revisited yet again. Blood. Sep 2008 112(6):2183-9.
6. Hettinger CM, Pötschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer. 2002 Jun;86(11):1763-9.
7. Grier HE Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 348:694-701.
8. Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000 342:137-8.
9. Kam MH, Eu KW, Barben CP, Seow-Choen F. Colorectal cancer in the young: a 12-year review of patients 30 years or less. Colorectal Dis. 2004 6:191-4.
10. AJ-Jaberi TM, Yaghan RJ, EI-Heis HA. Colorectal cancer in young patients under 40 years of age. Comparison with old patients in a well defined Jordanian population. Saudi Med J. 2003 8:871-4.
11. Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, et al. Colorectal Carcinoma in Childhood and Adolescence: A Clinicopathologic Review. J Clin Oncol. 2007 Dec 20;25(36):5808-5814.
12. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003 3:695-701.
13. Popat S, Hubner R, Houlston RS, Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005 23:609-18.
14. Chiang JM, Chen MC, Changchien CR, Chen JS, Tang R, Wang JY, et al. Favourable influence of age on tumour characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis. Colon Rectum. 2003 Jul 46:904-10.
15. Bleyer WA, O'Leary M, Barr R, Ries LAG, editors. Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767, Bethesda: National Cancer Institute and U.S. National Institutes of Health; 2006. Available from: www.seer.cancer.gov/ publications/aya.
16. Anders CK, Hsu HS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008 26:3324-30
17. Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, et al. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. Breast Ca Res. 2007. 9:R59 (doi:10.1186/bcr1765).
18. Anderson WF, Brinton LA, Chen B, Devesa SS. Qualitative age interactions (or effect modification) suggest divergent pathways for early-onset and late-onset breast cancers. J Clin Oncol. 2007 25(18S):21036a.
19. Bleyer A. Adolescent and young adult (AYA) oncology: The first A. Pediat Hemat Oncol. 2007 24:325-36.
20. Helwick J. Clinical trials struggle to recruit, retain patients. Oncol News International. Nov 1, 2008 17(11).
21. Bleyer A, Budd T, Montello M. Lack of clinical trial participation and of progress in older adolescents and young adults with cancer. Curr Probl Pediatr Adolesc Health Care. 2005 35(5):186-95.
22. Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer. 2005 103(9):1891-7.
23. Birch JM, Alston RD, Kelsey AM, Quinn JM, Babb P, McNally RJQ. Classification and incidence of cancers in adolescents and young adults in England 1979-1997. Br J Cancer. 2002 87:1267-74.
24. Bleyer A, Barr R, Phillips M, Siegel S, Albritton K. Challenges and opportunities - The way forward,. In Bleyer A, Barr RD, Albritton KH, Phillips M, Siegel S (Eds). Cancer in Adolescents and Young Adults, Springer Verlag, Berlin Hedelburg New York, 2007, pp. 505-17.
25. Bleyer A. Young adult oncology: The patients and their survival challenges. CA Cancer J Clin. 2007 57(4):242-55.